Scotia Capital’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Scotia Capital’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$334K	–	841
2023 Q3	$334K	Hold	50,000	–	–	﹤0.01%	622
2023 Q2	$453K	Sell	50,000 -325,000	-87%	-$2.87M	﹤0.01%	570
2023 Q1	$2.73M	Hold	375,000	–	–	0.02%	306
2022 Q4	$2.73M	Hold	375,000	–	–	0.02%	305
2022 Q3	$2.9M	Sell	375,000 -22,860	-6%	-$194K	0.02%	287
2022 Q2	$2.71M	Buy	397,860 +196,229	+97%	+$1.5M	0.02%	320
2022 Q1	$1.61M	Buy	+201,631	New	+$1.28M	0.01%	428

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Scotia Capital's PNT Position: Q4 2023 in Review

Scotia Capital sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 50,000 shares — an estimated $334K sold.

Scotia Capital first reported a position in PNT in Q1 2022 and held it in 7 quarters. The position peaked at $2.9M in Q3 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Scotia Capital reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Scotia Capital sold 50,000 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $334K.
Scotia Capital first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Scotia Capital's POINT Biopharma Global Inc. Common Stock position peaked at $2.9M in Q3 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Scotia Capital's 13F filing for Q4 2023, filed 12 Feb 2024.